In this work, two novel N-isopropylacrylamide (NIPAA)/Beta-cyclodextrin (β-CD)/WS2 and NIPAA/N, Ndimethyl acrylamide (DMAA)/WS2/βCD nanocarriers were prepared for in vitro tamoxifen drug release in the absence and presence of Near-Infrared (NIR) laser. The characterization of resulting nanocarriers was carried out using X-ray diffraction (XRD), Fourier transforms infrared spectroscopy (FTIR), field-emission scanning  electron  microscopy  (FE-SEM), and  thermogravimetric  analysis  (TGA).  To  study  the  effect  of temperature on drug release for chemotherapy, tamoxifen drug release was comparatively evaluated at three different  temperatures  (25,  37, and  50°C)  with  pH  7.4  in  the  absence  of a NIR  laser.  It  was  found  that tamoxifen release from  the  synthesized  nanocarriers at  50°C  was  significantly  greater than that  at  25  and 37°C. To investigate the effect of laser light on drug release for chemo-photothermal therapy, the in vitro release tests were carried out at 37°C with a NIR laser light and with a power density of 1 W/cm2for 5 min. The  increase  of  tamoxifen  release  after a laser  light  was  29.8%  and  48.4%for  NIPAA/βCD/WS2  and NIPAA/DMAA/βCD/WS2 samples, respectively. Thus, the combination of chemo/photothermal therapy had a  synergistic  effect  on  the  drug  release  of  tamoxifen.  Furthermore,  the  total  drug  release  of NIPAA/DMAA/βCD/WS2 was greater than that of NIPAA/βCD/WS2 nanocarrier. Furthermore, the kinetic release data were analyzed using Zero-order, First-order, Ritger-Peppas, and Higuchi models which followed the  zero-order  kinetic  release  model.  Also,  good  stability  was  observed  for  tamoxifen  in  the  drug  release system.